Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search

Pages

7776 items
12:38 PM, Oct 19, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Oxford Nanopore receives £50M investment from Amgen

Oxford Nanopore Technologies Ltd. (Oxford, U.K.) received an equity investment of £50 million ($65.6 million) on Oct. 18 from Amgen Inc. (NASDAQ:AMGN). Amgen's deCODE Genetics subsidiary uses Oxford Nanopore's nanopore-based DNA and RNA sequencing technology to...
11:21 AM, Oct 19, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Iovance closes $252M follow-on for Phase II trials

Iovance Biotherapeutics (NASDAQ:IOVA) closed a $252.2 million follow-on to fund five ongoing company-sponsored Phase II trials of its tumor infiltrating lymphocyte (TIL) cell therapies and prepare for potential launch of its lead TIL product. Iovance...
11:14 AM, Oct 19, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

PhaseBio, Osmotica price NASDAQ IPOs well below range

Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc (NASDAQ:OSMT) each priced IPOs well below their proposed ranges late Oct. 17. PhaseBio trading ended flat at $5 on Oct....
11:00 AM, Oct 19, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Led by ex-Afferent execs, CuraSen raises $54.5M series A

Neurodegenerative disease company CuraSen Therapeutics Inc. (San Mateo, Calif.) raised $54.5 million in a series A round on Oct. 17 led by New Leaf Venture Partners. Also participating were Longitude Capital, funds managed by Tekla...
10:50 AM, Oct 19, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Equillium prices $65.4M IPO

Autoimmune and inflammatory disease company Equillium Inc. (NASDAQ:EQ) raised $65.4 million in an IPO on Oct. 12 through the sale of 4.7 million shares at $14. Jefferies, Leerink and Stifel underwrote the offering. The company has...
10:46 AM, Oct 19, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Krystal raises $60M following Phase I/II gene therapy readout

On the heels of reporting data for its topical gene therapy, Krystal Biotech Inc. (NASDAQ:KRYS) raised $60 million late Oct. 18 through the sale 3 million shares at $20 in a follow-on underwritten by Cowen,...
10:06 AM, Oct 19, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Velicept raises additional $15M in series B

Velicept Therapeutics Inc. (Malvern, Pa.) raised $15 million in a series B round extension led by Samsara BioCapital. Existing investors CDK, Fountain Healthcare, Longitude Venture Partners and Becker Ventures also participated. Becker Ventures is Velicept's...
10:05 AM, Oct 19, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Verastem raises $150M in notes offering

Verastem Inc. (NASDAQ:VSTM) raised $150 million on Oct. 11 through the sale of 5% convertible senior notes due 2048. The notes have an initial conversion price of about $7.16, which is a 14% premium to...
11:18 AM, Oct 12, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Gene therapy company Audentes raises $151M

On the heels of data for one of its gene therapies, Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $150.8 million on Oct. 10 through the sale of 5.2 million shares at $29 in a follow-on underwritten by...
11:13 AM, Oct 12, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Immunometabolism company Sitryx debuts with GSK ties, $30M

Sitryx Therapeutics Ltd. (Oxford, U.K.) emerged from stealth on Oct. 8 with $30 million from a series A round to develop disease-modifying therapeutics for immuno-oncology and immuno-inflammation, which CEO Neil Weir expects to be enough...

Pages